I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 4.64 M.
EPS: As of FY2026 Q2, the actual value is USD -0.13, beating the estimate of USD -0.1699.
EBIT: As of FY2026 Q2, the actual value is USD -42.33 M.
Financial Results for the Three Months Ended June 30, 2026
Revenue
Collaboration revenue - related party was $4,640 thousand for the second quarter of 2026, compared to $0 for the same period in 2025.
Operating Expenses
Research and development expenses were $30,721 thousand for the second quarter of 2026, a decrease from $40,156 thousand in the second quarter of 2025. General and administrative expenses were $20,839 thousand for the second quarter of 2026, up from $14,281 thousand in the second quarter of 2025. Impairment of long-lived assets was $0 in the second quarter of 2026, compared to $2,382 thousand in the second quarter of 2025. Total operating expenses were $51,560 thousand for the second quarter of 2026, down from $56,819 thousand in the second quarter of 2025.
Operating Profit / Loss
Loss from operations was - $46,920 thousand for the second quarter of 2026, an improvement from - $56,819 thousand in the second quarter of 2025.
Other Income (Expenses), Net
Interest and other income, net, was $4,647 thousand for the second quarter of 2026, compared to $6,187 thousand in the second quarter of 2025. Interest expense was - $343 thousand for the second quarter of 2026, compared to - $268 thousand in the second quarter of 2025. Other income (expenses), net, was - $61 thousand for the second quarter of 2026, compared to - $43 thousand in the second quarter of 2025. Total other income (expenses), net, was $4,243 thousand for the second quarter of 2026, compared to $5,876 thousand in the second quarter of 2025.
Net Income / Loss
Net loss for the second quarter of 2026 was - $42,677 thousand, an improvement from - $50,943 thousand in the second quarter of 2025. Non-cash stock-based compensation expense totaled $12.4 million for the second quarter of 2026, which included $2.1 million in research and development and $10.3 million in general and administrative expenses.
Balance Sheet Data
Cash, cash equivalents and investments were $423,590 thousand as of June 30, 2026, compared to $258,253 thousand as of December 31, 2025. Total assets were $550,091 thousand as of June 30, 2026, up from $415,905 thousand as of December 31, 2025. Total liabilities were $113,916 thousand as of June 30, 2026, down from $123,363 thousand as of December 31, 2025. Total stockholders’ equity was $436,175 thousand as of June 30, 2026, compared to $292,542 thousand as of December 31, 2025.
Operational Metrics
Cema-Cel (Pivotal Phase 2 ALPHA3 Program in 1L LBCL)
An interim futility analysis supported cema-cel’s potential as an outpatient, MRD-guided 1L consolidation therapy. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for cema-cel. At the data cutoff, 58.3% (7⁄12) of patients in the cema-cel arm achieved MRD negativity, compared to 16.7% (2⁄12) in the observation arm, representing a 41.6% absolute difference. Cema-cel was well-tolerated with no treatment-related serious adverse events, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease (GvHD), or high-grade infections. Allogene Therapeutics, Inc. achieved its 2026 goal of activating over 80 sites approximately six months ahead of schedule, with approximately 100 sites now expected by year-end.
ALLO-329 (Phase 1 RESOLUTION Trial in Autoimmune Disease)
Enrollment continues at a brisk pace across dose escalation and lymphodepletion optimization cohorts.
Outlook and Guidance
Allogene Therapeutics, Inc. projects its cash runway into 2029 based on its cash, cash equivalents, and investments as of June 30, 2026. The company expects 2026 operating expenses to be approximately $165 million, with GAAP Operating Expenses estimated at approximately $225 million, including about $35 million in non-cash stock-based compensation. Updates for the ALPHA3 program are anticipated in mid-2027 with trial enrollment completion by year-end 2027, while a clinical data update for the ALLO-329 program is expected in the fourth quarter of 2026.